报价延迟最少15分钟:2026/08/25 11:20 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.19 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.48/1.51
|
|
企业价值
11.23B
|
| 资产负债 |
|
每股账面净值
17.85
|
| 现金流量 |
|
现金流量率
0.07
|
| 损益表 |
|
收益
5.10B
|
|
每股收益
11.11
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
